Camel-IDS
Developing radio-immunotherapeutic drugs for cancer patients.
Camel-IDS has raised €37M across 1 funding round from 2 investors, most recently a Series A round in Nov 2018. Based in Brussels, Belgium; founded 2014; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€37M
€37,000,000
Funding rounds
1
Investors
2
distinct backers
Active since
2018-11
latest 2018-11
Funding by year
EUR raised per yearCamel-IDS — funding by year — interactive chart.
Data table
| Camel-IDS — funding by year | |
|---|---|
| 2018 | €37M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2018-11-21 | Series A | €37M | GIMV,V-Bio Ventures | View deal → |
Investors
2Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Imec€2.5BBelgium · Deeptech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Kpler€1.0BBelgium · Software
Global coverage: FundingData